ABSTRACTS OF SCIENTIFIC MEETING

More than 130 abstracts at Local South African and International Scientific Meetings (including ASCO, MASCC and ESMO).

2019 ABSTRACTS

2018 ABSTRACTS

2017 ABSTRACTS

ABSTRACTS ARCHIVE

R. J. Gralla, B. L. Rapoport, K. Jordan, J. C. Street and A. Carides Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: Analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs). Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 15_suppl (May 20 Supplement), 2010: 9057

R. Gralla, B. Rapoport, C. Brown, J.C. Street, J.S. Hardwick, A.D. Carides. Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) in breast and non-breast cancers European Journal of Cancer Supplements, Volume 7, Issue 3, September 2009, Pages 23–24, Joint ECCO 15 – 34th ESMO Multidisciplinary Congress — Presidential sessions Late breaking and Best of ECCO 15 – ESMO 34 Abstracts and Best of 2009 Abstracts. 57LBA

B. L. Rapoport, D. A. Vorobiof, C. Slabber, G. Cohen, A. S. Alberts and H. S. Hlophe. Phase II study of combination therapy with pegylated liposomal doxorubicin (PLD)and carboplatin in patients (pts) with relapsed, platinum sensitive and platinum semi-sensitive ovarian cancer Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 5555
D. A. Vorobiof, B. L. Rapoport, H. S. Hlophe, C. F. Slabber and A. S. Alberts Phase II study of first line combination therapy with pegylated liposomal doxorubicin (PLD) and carboplatin in patients (pts) with extensive disease small cell lung cancer(ED SCLC) Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 26, No 15S (May 20 Supplement), 2008: 19089.
B. L. Rapoport, D. A. Vorobiof, C. Slabber, G. Cohen, A. S. Alberts and H. S. Hlophe. Phase II study of combination therapy with pegylated liposomal doxorubicin (PLD) and carboplatin in patients (pts) with relapsed, platinum sensitive and platinum semi-sensitive ovarian cancer. IGCS 2008, the 12th International Gynecologic Cancer Society Meeting (IGCS), Bangkok, Thailand, October 25-28, 2008.

Vorster A, Rodrigues S, Slabber CF, Rapoport BL. Metastatic breast cancer: Multivariate analysis of outcome over 3 decades. Proc S Afr Soc Clin Rad Oncol & S Afr Soc Med Oncol, Wild Coast Sun, pg 32 (#31), 2005Uys A, Rapoport B L, Fickl H, Meyer P, Anderson R. Procalcitonin (PCT) as an adjunct to the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score in cancer patients with febrile neutropenia. Proc Amer Soc Clin Oncol, (#8120), 2005B. L. Rapoport, C. F. Slabber, G. Cohen, G. McMichael, A. S. Alberts, D. A. Vorobiof and A. Uys. Phase II study of combination therapy with CHOP Interferon (IFN) alpha and rituximab (R) in chemo-naive patients (pts) with diffuse large B cell non-Hodgkin’s lymphoma (NHL). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1 Supplement), 2005: 6694 © 2005 American Society of Clinical Oncology.

Vorobiof D A, Rapoport B, Slabber C, Eek R, Cohen G, Alberts A S, McMichael G B, Raats J, Uys A. Phase II study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer. Proc Amer Soc Clin Oncol. (#5091), pg 470, 2004

Rapoport B L, Slabber C, Vorobiof D A, Alberts A S, Uys A. Phase II study of combination therapy with liposomal doxorubicin and carboplatin in patients with previously untreated small cell lung cancer. Proc Amer Soc Clin Oncol. (#7349), pg 700, 2004

J. Tester, P. Stephenson, C. J. Langer, J. H. Schiller, D. H. Johnson and B. L. Rapoport. ECOG 1599: Randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7055

Vorobiof DA, Rapoport BL, Mahomed R, Uys A, Slabber C, Eek R, Cohen G, Alberts AS, Raats J. A Phase II second line study of liposomal doxorubicin and carboplatin in patients with recurrent ovarian cancer with a disease free interval equal of greater than 6 months. Proc Eur Clin Cancer Org, (#179), pg S57, 2003

Langer, C.J., Stephenson, P., Schiller, J., Tester, W.J., Rapoport, B.L., Johnson, D.H.: ECOG 1599: Randomized Phase II Study of Paclitaxel/Carboplatin Vs Cisplatin/Gemcitabine in Performance Status (PS) 2 Patients with Treatment-Naive Advanced NSCLC [abstract]. Proceedings of the IASLC 2003. Abstract O-52. [E1599]

Paesmans M, Barette M, Rapoport B, Slabber C, Plehiers B, Alexopoulos C, Dubreucq L, Georgala A, Muanza F. Are lung cancer patients (pts) with febrile neutropenia (FN) different from other solid tumor pts? An analysis according to the MASCC score predicting risk of serious medical complication. IASLC conference, (#O-250), pg S73, 2003

Vorobiof D A, Chasen M R, McMichael G B, Mahommed C, Rapoport B L, Eek R, Slabber C. Multicenter Phase II study with caelyx and paclitaxel (taxol) as first line therapy in patients with advanced breast cancer. Caelyx Investigators Forum, Cannes, France, 3-5 April 2003

Vorobiof D A, Rapoport B L, Mahommed R, Uys A, Alberts A S, Cohen G L, eek R, Chasen M R, Slabber C F, Raats J I. Phase II study of combination therapy with caelyx and carboplatin in patients with relapsed, platinum sensitive ovarian cancer and a drug free interval > 6 months. Caelyx Investigators Forum, Cannes, France, 3-5 April 2003

Rapoport B L, Uys A, Anderson R. Febrile Neutropenia: Prospective study to validate the MASCC (Multinational Association for Supportive Care) risk index score. Proc Amer Soc Clin Oncol 22: Page 736, 2003 (#2960)

Uys A, Rapoport B L, Fickl H, Meyer R, Anderson R. Prospective study of serum pro inflammatory cytokine- and acute phase reactants in cancer paitents with febrile neutropenia. Proc Amer Soc Clin Oncol 22: page 736, 2003 (#2959)

Klastersky J, Rapoport B, Maertens J, Slabber C, Ferrant A, de Bock R, Georgala A, Uanza F, Vekemans M, Barette M. Characterization of the high-risk febrile neutropenic cancer patients as predicted by the MASCC risk-index score. Proc Amer Soc Clin Oncol, (#2118), 2003

Vorobiof D A, Chasen M R, McMichael G B, Mohammed C, Rapoport B L, Eek R, Slabber C. Multicentre phase II study with pegylated liposomal doxorubicin (PLD) and paclitaxel (T) As first line therapy in patients (pts) with a advanced breast cancer (ABC). Proc Amer Soc Clin Oncol, (#195), 2003

Paesmans M, Rapoport B, Maertens J, Slabber C, Ferrant A, Wingard J, Aoun M, Dubreucq L, Plehiers B, Klastersky J. Multicentric prospective validation of the mascc risk-index score for identification of febrile neutropenic cancer patients at low-risk for serious medical complications. Proc Amer Soc Clin Oncol, (#2235), 2003

Rapoport B L, Uys A, Anderson R. Febrile neutropenia : Prospective study to validate the MASCC (Multinational Association for Supportive Care in Cancer) risk-index score. Proc Supportive Care in Cancer, (#A165), pg 431, 2003

Uys A, Rapoport B L, Fickl H, Meyer P, Anderson R. Prospective study of serum pro inflammatory cytokine and acute phase reactants in cancer patients with febrile neutropenia. Proc Supportive Care in Cancer, (#A169), pg 432, 2003

Mahomed R, Rapoport B L, Slabber C, Vorobiof D, Landers G, Uys A, Raats J. Significant responses in patients with metastatic breast cancer refractory to anthracycline and taxane therapy. Results of a Phase I/II clinical trial of Cisplatin and raltitrexed. . Proc S Afr Soc Med Oncol, (#8), pg 8, 2003

Rapoport B L, Vorobiof D A, Mahomed R, Uys A, Slabber C, Alberts A S, Mare R. A Phase II study of Caelyx and carboplatin in patients with extensive stage small cell lung cancer. Proc S Afr Soc Med Oncol, (#20), pg 19, 2003

Rapoport B L, Vorobiof D A, Mahomed R, Uys A, Slabber c, Eek R, Cohen G, Alberts A S, Raats J. A Phase II second line study of liposomal doxorubicin (Caeylx) and carboplatin (CBDCA) in patients with recurrent ovarian cancer with a disease free interval equal or greater than 6 months. Proc S Afr Soc Med Oncol, (#22), pg 21, 2003

DA Vorobiof, B L Rapoport, M R Chasen, G M McMichael R Eek, C Slabber, C Mohammed. Phase II trial of Pegylated Liposomal Doxorubicin and Paclitaxel as first line therapy for patients with advanced breast cancer. Proc S Afr Soc Med Oncol, (#7), pg 7, 2003

Cohen G, Rapoport B L, Martin R, Mohammed R, Eek R, Chasen M, Slabber C. Biochemotherapy for metastatic malignant melanoma. A retrospective analysis of treatment outcome and long term follow-up. Proc S Afr Soc Med Oncol, (#75), pg 66, 2003

Mahomed R, Rapoport B L, Slabber C F, Vorobiof D A, Landers G, Uys A, Raats J. Siginificant responses with Cisplatin based therapy in patients with metastatic breast cancer refractory to anthracycline or anthracycline and taxanes : results of a phase I/II trial of cisplatin and raltitrexed. Proc Amer Soc Clin Oncol, 21, (#1999), pp 47b, 2002

Raats J, Rapoport B, Mahomed R, Uys A, Slabber C, Eek R, Landers G. A Phase I/II clinical trial of Cisplatin and raltitrexed (Tomudex) in newly diagnosed patients with metastatic carcinoma of unknown primary (CUP). Proc Amer Soc Clin Oncol (#2193), pg 95b, 2002

Vorobiof D A, Rapoport B L, Jacobs C, Chasen M R, Eek R, Cohen G, Mahomed R, Uys A. A Phase II first line study of docetaxel and carboplatin (CBDCA) in patients with advanced ovarian cancer. Combined SASMO / SASRO Congress, Muldersdrift, Sept 2001

Rapoport B L, Mahomed R, Slabber C, Vorobiof D, Landers G, Uys A, Raats J. Significant responses in patients with metastatic breast cancer refractory to anthracycline and taxane therapy. Results of a Phase I/II clinical trial of cisplatin, and raltitrexed (Tomudex). Combined SASMO / SASRO Congress, Muldersdrift, Sept 2001

Rapoport B L, Biganzoli L, Cufer T, Bruning P, Coleman R, Calvert H, Gamucci T, Twelves C, Donato di Paola D, Duchateau L, Yague C, Epelbaum R, Piccart M. EORTC 10961 : Doxorubicin (A) / Taxol (T) versus Doxorubicin (D) / Cyclophosphamide (C) as first line chemotherapy in metatastatic breast cancer (MBC) (A Phase III study). Combined SASMO / SASRO Congress, Muldersdrift, Sept 2001

Rapoport B L, Mahomed R, Uys A, Raats J, Eek R, Slabber C, Cohen G, Landers G. A Phase I/II clinical trial of cisplatin and raltitrexed (Tomudex) in newly diagnosed patients with metastatic carcinoma of unknown primary (CUP). Combined SASMO / SASRO Congress, Muldersdrift, Sept 2001

Littlewood T J, Bajetta E, Nortier J W R, Vercammen E, Rapoport B. Epoetin alpha in cancer related anaemia : Effects of epoetin alpha in haematologic parameters, quality of life and possible survival benefits in cancer patients receiving non-platinum chemotherapy : Results of a randomized double-blind, placebo-controlled trial. Combined SASMO / SASRO Congress, Muldersdrift, Sept 2001

Biganzoli L, Cufer T, Bruning P, Coleman R E, Duchateau L, Rapoport B, Nooij M, Delhaye F, Ellis P, Sulkes A, Piccart M. Doxorubicin-Paclitaxel : A safe regimen in terms of cardiac toxicity in metastatic breast cancer patients. Results from an EORTC multicenter trial. Combined SASMO / SASRO Congress, Muldersdrift, Sept 2001

Rapoport B L, Biganzoli L, Cufer T, Bruning P, Coleman R, Calvert H, Gamucci T, Twelves C, Donato di Paola D, Duchateau L, Yague C, Epelbaum R, Piccart M. EORTC 10961 : Doxorubicin (A) / Taxol (T) versus Doxorubicin (D) / Cyclophosphamide (C) as first line chemotherapy in metatastatic breast cancer (MBC) (A Phase III study). Combined SASMO / SASRO Congress, Muldersdrift, Sept 2001

Klastersky J, Paesmans M, Rubenstein E B, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston Km Talcott J. MASCC : The multinational association for supportive care in cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Combined SASMO / SASRO Congress, Muldersdrift, Sept 2001

Raats J, Rapoport B L, Mahomed R, Uys A, Eek R, Slabber C, Falkson C I, Landers G, Moodley D. A Phase I/II clinical trial of cisplatin and raltitrexed in newly diagnosed patients with metastatic carcinoma of unknown primary. Proc Amer Soc Clin Oncol, (#2292), 2001

Rapoport B L, Mahomed R, Uys A, Falkson C I, Landers G, Raats J. Significant responses in patients with metastatic breast cancer refractory to anthracycline therapy : Preliminary results of a Phase I/II clinical trial of cisplatin and raltitrexed. Proc Amer Soc Clin Oncol (#1927), 2001

Rapoport B L, Mahomed R, Uys A, Raats J. A Phase I/II clinical trial of cisplatin and ralititrexed (Tomudex) in newly diagnosed patients with metastatic carcinoma of unknown primary. . Proc S Afr Soc Med Oncol / Proc S Afr Soc Radiat Oncol, pg 16, March 17-19, 2000

Rabe J, Rapoport B L. Clinical activity and benefit of Irinotecan (CPT-11) in patients with colorectal cancer failing 5-flurouracil (5-fu), results of single institution. Proc S Afr Soc Med Oncol / Proc S Afr Soc Radiat Oncol, pg 18, March 17-19, 2000

Mahomed R, Rapoport B L, Uys A. A Phase I/II trial of cisplatin and raltitrexed (Tomudex) in patients with metastatic breast cancer refractory to anthracycline therapy. Proc S Afr Soc Med Oncol / Proc S Afr Soc Radiat Oncol, pg 30, March 17-19, 2000

Rapoport B L, Vorobiof D A, Jacobs C, Mahomed R, Uys A. A Phase II study of docetaxel (Taxotere) and carboplatin in patients with ovarian cancer not previously treated with chemotherapy. Proc S Afr Soc Med Oncol / Proc S Afr Soc Radiat Oncol, pg 44, March 17-19, 2000

Rapoport B L, Vorobiof D A, Chasen M, Ruff P, Fourie L, Mohamed R, Uys A. Treatment of Philadelphia Chromosome-positive early chronic phase. Chronic myelogenous leukemia with daily doses of interferon alpha and YNK-01 (oral cytarabine). Preliminary results of a Phase I/II study. The South African CML Study Group. A SASMO CTG clinical study. Proc S Afr Soc Med Oncol / Proc S Afr Soc Radiat Oncol, pg 46, March 17-19, 2000

Rapoport B L, Simons T, Mahomed R, Uys A. High dose cyclophosphamide, etoposide and carboplatin (CEC) for patients undergoing autologous peripheral blood stem cell transplants. Proc S Afr Soc Med Oncol / Proc S Afr Soc Radiat Oncol, pg 48, March 17-19, 2000

Rapoport B L, Uys A. Malaria parasitemia associated with febrile neutropenia in African patients undergoing chemotherapy for haematological malignancies. A report of three patients. Proc S Afr Soc Med Oncol / Proc S Afr Soc Radiat Oncol, pg 78, March 17-19, 2000

Rapoport B L, Rabe J. Interleukin-2 (Aldesleukin) in the treatment of metastatic malignant melanoma and metastatic renal cell carcinoma. Proc S Afr Soc Med Oncol / Proc S Afr Soc Radiat Oncol, pg 79, March 17-19, 2000

Uys A, Rapoport B L. Conducting clinical trials in Medical Oncology. Proc S Afr Soc Med Oncol / Proc S Afr Soc Radiat Oncol, pg 83 March 17-19, 2000

Klastersky J, Paesmans M, Rubenstein E B, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational associationf or supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038-3051, 2000

Raats J, Rapoport B L, Mahomed R, Uys A. A Phase I clinical trial of cisplatin and ralritrexed in newly diagnosed patients with metastatic carcinoma of unknown primary (CUP). Proc Eur Soc Med Oncol, Annals Oncol 11: (Suppl), 137, 2000

Rapoport B L, Mahomed R, Uys A. A Phase I/II trial of cisplatin, and ralititrexed in patients with metastatic breast cancer refractory to anthracycline therapy. Proc Eur Soc Med Oncol, Annals Oncol, 11: (Suppl) 34, 2000

Uys A, Rapoport B L. High volume leucopheresis : Good hematological recovery on patients undergoing autologous perpheral blood stem cell transplants. Proc Amer Soc Clin Oncol (#247), pg 66a, 1999

Rapoport B L, Herrera M V, Sussmann O, Iglesias L, Otero R J C, Pavlovsky S, Schlaeffer F, Stein G, Charnas R, Heitlinger E, Handschin J C. Multinational open label comparative study of inpatient (IP) versus outpatient (OP) treatment (TX) in neutropenic cancer patients (PTS) with presumed infection with empiric ceftriaxone plus an aminoglycoside (AG) and filgrastim (F): A test of criteria for early hospital discharge. Proc Amer Soc Clin Oncol (#2270), pg 588a, 1999

Adverse Effects of Alpha 2b Interferon (IFN) in Patients with Ph+ Early Chronic-phase Chronic Myelogenous Leukemia Enrolled in the International Oncology Study Group (IOSG) CML1 Study. F.J. Giles, P.M. Shah, G.Y. Tee, L.X. Wang, A. Cavilez, Jr., I. Supandiman, F. Rana, B.L. Rapoport, Z. Fahed, Z. Aziz, C. Suharti, Y.C. Chen, P. Tan, K.A. Salim, V. Kochupillai, M. Gonzaga, N.M. Ali, S.H. Advani, M. Patel, S. Chen, R. Torres, J. Tam, A.M. Lynott, S.W. Lim, M.P. Fuerst, D.A. Kusuanco and V. Poovalingam. Submitted to the 1998 ISH-EHA Combined Congress Amsterdam, The Netherlands, July 4-8, 1998.

Prognostic Factors in Patients with Ph+ Early Chronic-phase Chronic Myelogenous Leukemia (Cml) Enrolled in the International Oncology Study Group (Iosg) Cml1 Study. F.J. Giles, A. Lynott, P.M. Shah, L.X. Wang, I. Supandiman, Z. Fahed, F. Rana, B.L. Rapoport, Z Aziz, S.H. Advani, M. Patel, C. Suharti, Y.C. Chen, P.J. DuToit, H. Januszewicz, G.Y. Tee, M. Wolf, R. Sumantri, K. Al-Omari, B.S. Ho., D. Tian, W.R. Bezwoda, E. Abdi, M. Gonzaga, F. Fahed, L.S. Fourie, S.W. Lim, D.A. Kusuanco and A. Cavilez, Jr. Submitted to the 1998 ISH-EHA Combined Congress Amsterdam, The Netherlands, July 4-8, 1998.

Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Aapro MS, Alaki M, Murawsky M, Riva A. On Behalf of the International 304 study Group. Taxotere improves survival over mitomycin C and vinblastine in patients with metastatic breast cancer who have failed an antracycline containing regime. Final results of a phase III randomized trial. 1998 American Society of Clinical Oncology (ASCO) Annual Meeting, Los Angeles, CA, USA, May 1998. Published in the Journal of Clinical Oncology. Vol 17, abstract number 390, page 101a.

Neoadjuvant dose intensive chemotherapy in locally advancede breast cancer (LABC): An EORTC-NCIC-SAKK randomized phase III comparing FEC (5FU, epirubicin, cyclophosphamide) versus high intensity EC (epirubicin and cyclophosphamide) and G-CSF.(EORTC Study 10921) BL Rapoport, P. Therasse. L. Muriac, M. Welnicka, P Brunning, T. Cufer, H. Bonnefol, E. Tomiak, A. Hamilton, M. Piccart. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Capetown. October 2-6, 1998.

Campto (CPT-11) with or without Granocyte (lenograstim) in the treatment of metastatic colorectal cancer (MCRC): The South African Data. Callaghan RM, Rapoport B, Vorobiof D, Brennan S, Landers G, Heslop L, Jacobs C, Van der Merve A, Bezwada W, Falkson C, Pienaar R, Raats J, Jordan JP. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Capetown. October 2-6, 1998.

Interleukin-2 (aldesleukin) in the treatment of metastatic malignant melanoma and renal cell carcinoma. BL Rapoport. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Cape Town. October 2-6, 1998.

Gemcitabine and Carboplatin in patients with advanced malignancies. J Rabe, BL Rapoport. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Cape Town. October 2-6, 1998.

Multicentric double blind comparison of intravenous and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. BL Rapoport, L Goedhals, P Ruff, DA Vorobiof. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Cape Town. October 2-6, 1998. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Cape Town. October 2-6, 1998.

Factors affecting time to hematological recovery on patients undergoing autologous peripheral blood stem cell transplants who have been mobilized with G-CSF at a dose of 10 micrograms per kg for a total of 6 days. BL Rapoport. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Cape Town. October 2-6, 1998.

Prognostic Factors for the outcome in cancer patients with febrile neutropenia: A multinational survey from the infection committee of the multinational association for suppotive care of cancer (MASCC). J Klastersky and BL Rapoport for the MASCC. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Cape Town. October 2-6, 1998.

Open label comparative study of inpatient versus outpatient treatment in cancer patients with presumed infection with empiric ceftriaxone plus an aminoglucoside and filgrastim (G-CSF): A test criteria for early hospital discharge. Final Report. BL Rapoport, A Forero, RJC Otero, S Pavlovsky, F Schlaeffer, A Uys. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Cape Town. October 2-6, 1998.

Therapy of HIV-Related Non-Hodgkin’s Lymphoma: An European Multicentric randomized study in patients stratified according to their prognostic factors: Preliminary Results. BL Rapoport, C Gisselbrececht, M Spina, G Gabarre, G Rizzardini, D Schaifer, E Nigra, R Bouabdallah, M Schrappe, C Carbone, M Raphael, and U. Tirelli. Combined SASMO/SASRO and SALSG Congress. Arthur’s Seat Hotel, Cape Town. October 2-6, 1998.

Krzakowski M, Graham E, Goedhals L, Joly F, Pawlicki M, Rapoport B, Yelle L, Lees J, McQuade B A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group. Anticancer Drugs 1998 Aug;9(7):593-598

Slabber C F, Falkson CI, Pritzlaff A, Rapoport B L. A Phase II study of low dose interferon alpha maintenance in chronic myeloid leukemia. Proc Amer Soc Hematology (#4072), 1998

Callaghan R M, Rapoport B, Vorobiof D, Brennan S, Landers G, Heslop L, Jacobs C, van der Merwe A, Bezwoda W, Falkson C, Pienaar R, Raats J, Jordaan J P. CAMPTO (CPT-11) with or without Granulocyte (lenograstim) in the treatment of metastatic colorectal cancer (MCRC) : The South African Data. Combined SASMO / SASRO / SALSG Congress, Cape Town, pg 33, 2-6 October 1998

EORTC: Paclitaxel plus cisplatin versus tenoposide plus cisplatin in the treatment of non small cell lung cancer. G. Giancone, TAW Splinter, PE Postmus, M Diaz-Puente, N van Zandwijk, G. Scagliotti, A. Ardizoni, J. van Meerbeeck, T Sahmoud, and BL Rapoport on behalf of the EORTC Lung Cancer Cooperative Group. Combined SASMO/SASRO Congress. Durban. March, 1997.

A multicentre, double-blind, double-dummy, randomized parellel group study to compare the efficacy and safety of ondansetron tablets and ondansetron zydis in the control of emesis and nausea induced cyclophosphamide-containing chemotherapy treatment in cancer patients. BL Rapoport, P Ruff, Vorobiof D, L Goedhals. Combined SASMO/SASRO Congress. Durban. March, 1997.

Open label comparative study of inpatient versus outpatient treatment in cancer patients with presumed infection with empiric ceftriaxone plus an aminoglucoside and filgrastim (G-CSF): A test criteria for early hospital discharge. BL Rapoport, Charnas R, Uys A, Heitlinger E. Combined SASMO/SASRO Congress. Durban. March, 1997.

Therapy of HIV-Related Non-Hodgkin’s Lymphoma: An European Multicentric randomized study in patients stratified accordind to their prognostic factors: Preliminary Results. C Gisselbrececht, M Spina, G Gabarre, G Rizzardini, D Schaifer, E Nigra, R Bouabdallah, M Schrappe, BL Rapoport, C Carbone, M Raphael, and U. Tirelli for the European Intergroup. National Aids Malignancy Conference. National Cancer Institute. Bethesda, Maryland, USA. April 28-30, 1997.

A Prospective Randomized Trial of Hydroxyurea plus Alpha 2b Interferon (IFN) versus Ara-C plus IFN in Ph+ Chronic Myelogenous Leukemia (CML) Patients: The International Oncology Study Group (IOSG) CML1 Study. FJ Giles, KA Salim, V Poovalingam, BL Rapoport, I Supandiman, PM Shah, F Rana, M Patel, Z Aziz, P Tan, V Kochupillai, Z Fahed, SH Advani, GY Tee, A Cavilez , M Franco, Fuerst, J Tam, D Kusuanco and SW Lim. Oral presentation. XIVth Meeting of the International Society of Haematology, European and African Division, Stockholm, Sweden, Aug 30-Sept 4, 1997.

A Prospective Randomized Trial of Interferon Maintenance in Multiple Myeloma: The International Oncology Study Group MM1 Study. FJ Giles, H Akan, NR Wickham, P Ruff, C Suharti, I Supandiman, BL Rapoport, V Kochupillai, C Suh, PM Parikh, A Muthalib, J Raafat, N Uskent, MP Fuerst, JT Tam, MM Franco, DA Kusuanco and SW Lim. Poster presentation. XIVth Meeting of the International Society of Haematology, European and African Division, Stockholm, Sweden, Aug 30-Sept 4, 1997.

Open label comparative study of inpatient versus outpatient treatment in cancer patients with presumed infection with empiric ceftriaxone plus an aminoglucoside and filgrastim (G-CSF): A test criteria for early hospital discharge. Final Report. BL Rapoport, A Forero, RJC Otero, S Pavlovsky, F Schlaeffer, A Uys. Third International Conference on Febrile Neutropenia. Brussels, Belgium. December 1997

Rapoport BL, Charnas R, Uys A, Heitlinger E. Comparative study of inpatient versus outpatient treatment in cancer patients with presumed infection with empiric ceftriaxone plus an aminoglucoside and filgrastim (Meeting abstract).
Proc Annu Meet Am Soc Clin Oncol (1996) 15:A1756 1996

Clinical Characteristics of Asian Multiple Myeloma Patients at Time of Diagnosis: An International Oncology Study Group (IOSG) Study. F.J. Giles, S.W. Lim, N.R. Wickham, I. Supandiman, C. Suh, C. Cuharti, A. Muthalib, P. Tan, C.H. Hee, V. Kochupillai, A. Harryanto R., A. Lekhakula, B.L. Rapoport, T.G. Sagar, K.A. Salim, D. Radheshyam, P. Ruff, C.H. Ho, J.H. Kim, Y.C. Chen, N. Suwansela, B.K. Smruti, M. Patel, S.Y. Kim, D. Tian, T. Thamprasit, K.B. Lee, H. Akan, R. Sumantri, C. Narciso, P.N. Wang, M.P. Fuerst, G.N. Lawrence and D.A. Kusuanco for the IOSG. Submitted to the 1996 American Society of Clinical Oncology (ASCO) Annual Meeting, Philadelphia, PA, USA, May 18-21, 1996.

Clinical Characteristics at Diagnosis of Asian Non-Hodgkin’s Lymphoma Patients on the International Oncology Study Group (IOSG) NHL1 Study. F.J. Giles, S.W. Lim, B. Chaimongkol, P.P. Bapsy, A. Villalon, S. Jootar, A. Harryanto R., T.G. Sagar, T. Thamprasit, S.W. Kim, C. Suh, H.S. Song, C. Suharti, A.P. Schwarer, S.Y. Kim, M. Roslan, A. Lekhakula, R. Kumar, T. Kannan, B.L. Rapoport, N.R. Wickham, N. Sotamaphan, T. Intragumtornchai, S.K. Cheong, J. Raafat, F.S. Esfahani, M.A. Coccia-Portugal, S. Chuncharunee, W. Prayoonwiwat, O. Doyeun, B.K. Smruti, C.W. Voges, P.M. Shah, M.P. Fuerst, G.N. Lawrence and D.A. Kusuanco. 1996 American Society of Clinical Oncology (ASCO) Annual Meeting, Philadelphia, PA, USA, May 18-21, 1996. Published in the Journal of Clinical Oncology.

Presenting Features of Chronic-Phase CML (CP CML): A Comparison Between Asian and U.S. Patients: An International Oncology Study Group (IOSG) Study. F.J. Giles, H.M. Kantarjian, S.W. Lim, K.A. Salim, B.L Rapoport, V. Poovalingam, I. Supandiman, V. Kochupillai, P. Tan, R. Torres, M. Gonzaga, Y.C. Chen, G.Y. Tee, L.L. Heng, C. Suharti, M. Patel, R. Sumantri, P.M. Shah, L.X. Wang, B.S. Ho, C. Shanshan, N. Ona, K.Y. Kim, M.P. Fuerst, G.N. Lawrence and D.A. Kusuanco for the IOSG. 1996 American Society of Clinical Oncology (ASCO) Annual Meeting, Philadelphia, PA, USA, May 18-21, 1996. Published in the Journal of Clinical Oncology.

Presenting Features of PH+ Chronic-Phase CML (CP CML): A Comparison between Asian and French Patients on the International Oncology Study Group (IOSG) CML1 Study and the French CML88 Study. F.J. Giles, K.A. Salim, B.L. Rapoport, V. Poovalingam, I. Supandiman, V. Kuchopillai, P. Tan, R. Torres, M. Gonzaga, Y.C. Chen, C.H. Ho, G.Y. Tee, L.L. Heng, C. Suharti, M. Patel, D. Tian, R. Sumantri, P.M. Shah, L.X. Wang, S.N. Lee, B.S. Ho, S. Chen, N. Ona, K.Y. Kim, S.W. Lim, M.M. Franco, M.P. Fuerst, G.N. Lawrence, D.A. Kusuanco and F. Guilhot for the IOSG and the Centre Hospitalier Universitaire de Poitiers. 2nd Meeting of the European Haematology Association (EHA), Paris, France, May 29-June 1, 1996. Published in the British Journal of Haematology.

Initial Characteristics of Chinese Patients on the International Oncology Study Group (IOSG) NHL1 Study. FJ Giles, D Tian, PM Chen, NB Chang, SH Wang, A Villalon, PP Bapsy, B Chaimongkol, J Raafat, S Jootar, A Harryanto R, T Taratorn, TG Sagar, SW Kim, C Suh, F Esfahani, AP Schwarer, A Muthalib, HS Song, C Suharti, BL Rapoport, A Lekhakula, V Kuchopillai, SY Kim, R Kumar, M R Haron, NR Wickham, T Intragumtornchai, T Kannan, SK Cheong, CW Voges, MA Coccia-Portugal, KB Lee, L Bellarmine, S Serdengecti, O Doyeun, BK Smruti, PM Shah, N Sotamaphan, V Jinarantana, Z Aziz, S Chuncharunee, W Prayoonwiwat, A Lim, KW Leong, KS Lam, BS Ho, P Ruff, DA Kusuanco, MM Franco. Oral presentation. The First National Congress of Hematological Oncology, May 6-8, 1996, Beijing, China.

The Chinese Patient Cohort in the International Oncology Study Group (IOSG) MM1 Study: Alphga 2b Interferon in Multiple Myeloma. F Giles, D Tian, S Chen, JY Ru, YC Chen, HF Tien, JY Chang, CH Ho, TY Chao, PN, Wang, NR Wickham, H Akan, J Raafat, N. Uskent, I Supandiman, P Ruff, C Suharti, C Suh, A Muthalib, P Tan, V Kochupillai, BL Rapoport, KB Lee, PM Parikh, KA Salim, A Harryanto R, D Radheshyam, TG Sagar, A Lekhakula, T Thamprasit, JH Kang, N Suwansela, BK Smruti, SY Kim, E. Anggraeni, R Sumantri, D Ragnuhardi, M Gonzaga, BK Gopal, C Narcisco, SH Kim, MR Chasen, N Ona, J Raats, S Comia, SW Lim, MP Fuerst, MM Franco, DA Kusuanco. Oral presentation. The First National Congress of Hematological Oncology, May 6-8, 1996, Beijing, China.

The International Oncology Study Group (IOSG) CML1 Study: Presenting Features of the Chinese Patient Cohort. FJ Giles, LX Wang, S Chen, D Tian, YC Chen, CC Wang, NB Chang, HF Tien, CH Ho, TY Chao, PC Dong, KA Salim, PM Shah, BL Rapoport, V Poovalingam, I Supandiman, P Tan, R Torres, M Gonzaga, V Kochupillai, GY Tee, Z Fahed, C Suharti, SH Advani, LL Heng, M Patel, R Sumantri, SN Lee, K Omari, MZ Abdul Hadi, BS Ho, N Ona, KY Kim, A Cavilez, Jr, S Comia, PM Parikh, Z Aziz, A Muthalib, HC Kim, WR Bezwoda, MY Kim, LS Fourie, M Saleem, H Januszewicz, M Wolf, SW Lim, MP Fuerst, DA Kusuanco, MM Franco. Oral presentation. The First National Congress of Hematological Oncology, May 6-8, 1996, Beijing, China.

Hydroxyurea plus Alpha 2b Interferon (IFN) versus Ara-C plus IFN for Ph+ Chronic Phase CML: The International Oncology Study Group (IOSG) CML1 Study. WR Bezwoda, KA Salim, PM Shah, BL Rapoport, V Poovalingam, I Supandiman, M Patel, LS Fourie, MP Fuerst, SW Lim, MM Franco, DA Kusuanco and FJ Giles. Oral presentation. 11th South African Lymphoma Study Group Symposium, “Lymphomas: Beyond 2000”, September 1-3, 1996.

Recombinant Alpha 2b Interferon (IFN) as Maintenance Therapy in Multiple Myeloma: The International Oncology Study Group (IOSG) MM1 Study. P Ruff, BL Rapoport, NR Wickham, H Akan, J Raafat, N Uskent, M Patel, MR Chasen, J Raats, SW Lim, MP Fuerst, MM Franco, DA Kusuanco and FJ Giles. Oral presentation. 11th South African Lymphoma Study Group Symposium, “Lymphomas: Beyond 2000”, September 1-3, 1996.

CHOP plus Interferon (IFN) Induction and IFN Maintenance Vs CHOP Induction Alone in Intermediate-Grade (IG) and High-Grade NHL: The International Oncology Study (IOSG) NHL1 Study. LS Fourie, A Villalon, PP Bapsy, B Chaimongkol, J Raafat, S Jootar, BL Rapoport, CW Voges, MA Coccia-Portugal, J. Raats, P Ruff, SW Lim, MM Franco, DA Kusuanco and FJ Giles. Oral presentation. 11th South African Lymphoma Study Group Symposium, “Lymphomas: Beyond 2000”, September 1-3, 1996.

Treatment of Relapsed or Refractory Multiple Myeloma (MM) with Cyclophosphamide, Etoposide, Vincristine, Adriamycin and Dexamethasone (CEVAD)/GM-CSF Followed by Maintenance Alpha 2b Interferon (IFN)/Dexamethasone. BL Rapoport, NR Wickham, W Fong, G Somlo, A Uys, HA Koh, MP Fuerst, MM Franco, SW Lim, DA Kusuanco and FJ Giles. Oral presentation. 11th South African Lymphoma Study Group Symposium, “Lymphomas: Beyond 2000”, September 1-3, 1996.

Phase II Study of Recombinant Alpha 2b Interferon as Maintenance Therapy in Patients with De Novo Multiple Myeloma (MM): The International Oncology Study Group (IOSG) MM1 Study. BL Rapoport, NR Wickham, H Akan, J Raafat, N Uskent, I Supandiman, P Ruff, C Suharti, C Suh, CH Ho, A Muthalib, P Tan, V Kochupillai, KB Lee, PM Parikh, KA Salim, A Harryanto R, D Radheshyam, TG Sagar, A Lekhakula, T Thamprasit, YC Chen, JH Kang, N Suwansela, BK Smruti, D Tian, SY Kim,E Anggraeni, PN Wang, R Sumantri, D Ragnuhardi, M Gonzaga, BK Gopal, C Narcisco, SH Kim, MR Chasen, N Ona, JI Raats, TY Chao, S Comia, SW Lim, MP Fuerst, MM Franco, DA Kusuanco and FJ Giles. Proceedings volume of the Multiple Myeloma: Advances in Biology and Treatment conference, Vienna, Austria, September 13-14, 1996.

CEVAD Therapy – a New Infusional Adriamycin-containing Combination for Refractory or Relapsed Multiple Myeloma: The International Oncology Study Group (IOSG) MMR2 Study. FJ Giles, SW Lim, NR Wickham, W Fong, G Somlo, P McAndrew, MP Fuerst, CE Hughlett, DA Fischer, MM Franco, A Uys, DA Kusuanco and BL Rapoport. Proceedings volume of the Multiple Myeloma: Advances in Biology and Treatment Conference Conference, Vienna, Austria, September 13-14, 1996.

A Comparison of Initial Clinical Characteristics between Asian and Italian Multiple Myeloma Patients Enrolled in the International Oncology Study Group (IOSG) MM1 and the Italian MM Study group Protccols. FJ Giles, G Avvisati, I Supandiman, NR Wickham, C Suh, C Suharti, A Muthalib, P Tan, CH Lee, V Kuchopillai, A Harryanto R, A Lekhakula, BL Rapoport, TG Sagar, H Akan, J Raafat, N Uskent, PM Parikh, KA Salim, D Radheshyam, P Ruff, CH Ho, JH Kim, YC Chen, N Suwansela, JH Kang, YC Chen, BK Smruti, M Patel, SY Kim, D Tian, T Thamprasit, KB Lee,M Gonzaga, R Sumantri, C Narciso, PN Wang, MR Chasen, JI Raats, TYChao, E Anggraeni, D Ragnuhardi, N Ona, BK Gopal, S Comia, MP Fuerst, SW Lim, MM Franco, DA Kusuanco. Blood, the 38th Annual Meeting, American Society of Hematology, Orlando, Florida, December 6-10, 1996

Treatment of Early Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Recombinant Alpha b Interferon (Intron) and Hydroxyurea (H) Versus Intron and Low-Dose Ara-C (C): An International Oncology Study Group (IOSG) Protocol. R.M. Look, K.A. Salim, B.L. Rapoport, C. Suharti, R. Sumantri, I. Supandiman, R. Torres, G.-Y. Tee, B.S. Ho., S.W. Lim, D.A. Kusuanco and F.J. Giles for IOSG. Presented at the 9th Symposium, Molecular Biology of Hematopoiesis, June 23-27, 1995. Acta Hematologica, Volume 93, 1995, 180.

Treatment of Multiple Myeloma (MM) Patients after an Objective Response to Induction Melphalan/Prednisone with Maintenance Recombinant Alpha 2b Interferon (Intron) Alone from Response to Relapse vs. Intron Alone for 1 Year from Response to Relapse vs. Intron combined with Monthly Pulse Dexamethasone from Response to Relapse: An International Oncology Study Group (IOSG) Protocol. R.M. Look, I. Supandiman, C. Suh, A. Muthalib, C. Suharti, B.L. Rapoport, P. Tan, Y.C. Chen, K.A. Salim, A. Harryanto R., D. Radheshyam, N. Suwansela, G. P. Ruff, S.W. Lim, D.A. Kusuanco and F.J. Giles for IOSG. Presented at the 9th Symposium, Molecular Biology of Hematopoiesis, June 23-27, 1995. Acta Hematologica, Volume 93, 1995, 196.

An International Oncology Study Group (IOSG) Protocol: Maintenance Therapy in de novo Multiple Myeloma (MM) Pts after an Objective Response to Induction Melphalan/Prednisone (MP) with Recombinant Alpha 2b Interferon (Intron) from Response to Relapse (Arm I) Vs. Intron for 1 Year from Response (Arm II) Vs. Intron + Pulse Dexamethasone from Response to Relapse (Arm III). A. Harryanto R., I. Supandiman, C. Suh, A. Muthalib, C. Suharti, B.L. Rapoport, K.A. Salim, P. Tan, Y.-C. Chen, D. Radheshyam, N. Suwansela, T.G. Sagar, P.R. Ruff, D. Kusuanco and F.J. Giles for the IOSG. Proceedings Volume of the VIII Congress of the Asia-Pacific Division of the International Society of Hematology, Brisbane, Australia, October 15-18, 1995.

An International Oncology Study Group (IOSG) Protocol: Treatment of Previously Untreated Intermediate-Grade (IG) and High-Grade (HG) NHL Patients with CHOP Plus Alpha 2b Interferon (Intron) Induction followed by Intron Maintenance Versus CHOP Induction Alone Versus CHOP Induction followed by COP Maintenance. S. Jootar, B. Chaimongkol, A. Villalon, T.G. Sagar, T. Thamprasit, C. Suh, A. Harryanto R., H.S. Song, P.P. Bapsy, A. Muthalib, C. Suharti, B.L. Rapoport, T. Kannan, D.A. Kusuanco and F.J.Giles for the IOSG. Proceedings Volume of the VIII Congress of the Asia-Pacific Division of the International Society of Hematology, Brisbane, Australia, October 15-18, 1995.

An International Oncology Study Group (IOSG) Protocol: Treatment of Previously Untreated Early Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Recombinant Alpha 2b Interferon (Intron) and Hydroxyurea Versus Intron and Low-Dose Ara-C. K.A. Salim, G.Y. Tee, R. Sumantri, B.L. Rapoport, C. Suharti, M. Patel, L.L. Heng, R. Torres, I. Supandiman, D.A. Kusuanco and F.J. Giles for the IOSG. Proceedings Volume of the VIII Congress of the Asia-Pacific Division of the International Society of Hematology, Brisbane, Australia, October 15-18, 1995.

Open label comparative study of inpatient versus outpatient treatment in cancer patients with presumed infection with empiric ceftriaxone plus an aminoglucoside and filgrastim (G-CSF): A test criteria for early hospital discharge. BL Rapoport, Charnas R, Uys A, Heitlinger E. Second International Conference on Febrile Neutropenia. Brussels, Belgium. December 1995.

Rapoport B L, Falkson G, Raats J I. Late complications of testicular cancer. An analysis of 184 survivors. Proc Amer Soc Clin Oncol 12: 236 (Abstract # 732), 1993

de Wet M, Rapoport B L, Falkson G. Factors predisposing to incomplete control of emesis in patients receiving repeat cycles of cytostatic therapy: A logistic regression analysis of 516 cycles of Granisetron. Proc Amer Soc Clin Oncol 12:
441 (Abstract # 1524), 1993

de Wet M, Rapoport B L, Falkson G. Continuation of Granisetron administration in patients receiving cytostatics. NCI/EORTC combined meeting. Annals of Oncology 3: 156 (#389), 1992.

Rapoport B L, Falkson G, Raats J I. Clinical Stage I testicular cancer: Clinical course. Proc Am Assoc Cancer Res 33: 219 (#1309), 1992.

Rapoport B L, Falkson G, Moeken C. Long term complications in patients with clinical Stage 1 non seminomatous testicular cancer. Proc Am Soc Clin Oncol 11: 302 (#628), 1992.

Ansell S M, Falkson G, Rapoport B L, Uys A, de Wet M. Age as a prognostic determinant in elderly patients with cancer. First International Conference on Geriatric Oncology, Buenos Aires, Argentina, (Abstract #1.6) October 2830, 1992.

KerenRosenberg S, Uys A, Rapoport B L, Falkson G, Stevens K. Recombinant Human Erythropoietin in the treatment of cancer related anaemia. 4th Biennial Conference on Chemotherapy of infectious disease and malignancies Prague, Czechoslovakia, Aug 30 Sept 1, 1992, (#305).

Rapoport B L, Falkson G, Raats J I, Moeken C M. Clinical stage I testicular cancer : Clinical course. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

Rapoport B L, Falkson G, Moeken C M. Long term complications of patients with clinical stage I non seminomatous testicular cancer. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

KerenRosenberg S, Falkson C I, Uys A, Rapoport B L. FIVB plus GMCSF in advanced colorectal carcinoma. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

Ansell S M, Rapoport B L, Raats J I, Moeken C M, Falkson G. Survival determinants in patients with advanced ovarian cancer. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

Rassalski T K, Rapoport B L, Uys A, Falkson G. Fludarabine in chronic lymphoproliferative disorders. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

KerenRosenberg S, Uys A, Rapoport B L, Falkson G, Stevens K. Recombinant human erythropoietin in the treatment of cancer related anaemia. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

CocciaPortugal M A, Uys A, Rapoport B L, Falkson G. A Phase II study of Mitoxantrone (DHAD), Cytosine Arabinoside and VP16 (MAV) induction and very early consolidation with GMCSF support in patients with untreated AML. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

CocciaPortugal M A, Rapoport B L, Uys A, Falkson G. Alpha 2B Interferon in the treatment of “ITPlike syndrome” in cancer patients. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

de Wet M, Rapoport B L, Falkson G. Continuation of Granisetron administration in patients receiving cytostatics. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

Rassalski T K, Rapoport B L, Uys A, Falkson G. Myleran induction followed by `2b Interferon maintenance in patients with chronic myeloid leukaemia. (A Phase II Study). Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

Rapoport B L, Falkson G, de Wet M, Ansell S. Suramin in combination with mitomycin C in hormone resistant prostate cancer. A Phase II clinical study. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

KerenRosenberg S, Raats J I, Rapoport B L, Falkson G. Somatostatin (Sandostatin) in the treatment of diarrhoea (as paraneoplastic syndrome) in lung cancer. Combined Congress S Afr Society of Medical Oncology/S Afr Society of Radiotherapist, Drakensberg Sun Hotel, April 1992.

de Jager L C, Rapoport B L, Ansell S M. Paediatric and adoloscent malignant nonHodgkin’s lymphomas. South African Lymphoma Study Group 6th Biennial Congress “Lymphoma in Africa” Johannesburg, 29 Aug1 Sept 1992.

Rassalski T K, Rapoport B L, Uys A, Falkson G. Fludarabine in chronic lymphoproliferative disorders. South African Lymphoma Study Group 6th Biennial Congress “Lymphoma in Africa” Johannesburg, 29 Aug1 Sept 1992.

Rapoport B L, Falkson G, Raats J I. Clinical Stage I Testicular Cancer: Clinical Course. The Urological Association of South Africa Nineteenth Congress, Sun City Bophuthatswana, 813 March, p 81, 1992.

Rapoport B L, Falkson G, Moeken C. Long term complications in patients with clinical Stage 1 non seminomatous testicular cancer. The Urological Association of South Africa Nineteenth Congress, Sun City Bophuthatswana, 813 March, p 81, 1992.

Ansell S M, Rapoport B L, Raats J I, Moeken C M, Falkson G. Oorlewingsbepaling in pasiente met gevorderde kanker van die ovarium. Fakulteitsdag, Universiteit van Pretoria, p P30, 1992.

CocciaPortugal M A, de Jager L C, Uys A, Rapoport B L, Falkson G. A’n Fase II studie waarin kombinasie intensiewe chemoterapie met granulosietmakrofaagkolonie stimulerende faktor (GMCSF) as beenmurgstimulant in onbehandelde pasiente met akute nonlimfoblastiese leukemie (ANLL) evalueer is. Fakulteitsdag, Universiteit van Pretoria, p P31, 1992.

de Jager L C, Rapoport B L, Ansell S M. Pediatriese en adolessente maligne NonHodgkin limfome. Fakulteitsdag, Universiteit van Pretoria, p P32, 1992.

Rassalski T K, Rapoport B L, Uys A, Falkson G. Fludarabien in die behandeling van chroniese limfatiese leukemie (CLL) en lae graadse limfome. Fakulteitsdag, Universiteit van Pretoria, p P33, 1992

Rapoport B L, Ansell S, CocciaPortugal M A, de Wet M, Falkson G. Phase II Clinical Study of Suramin in combination with MitomycinC in patients with hormone resistant prostate cancer. Proc Am Soc Clin Oncol 10: 177 (#572), 1991.

Rapoport B L, Falkson G, Ansell S M, de Wet M, Lotz B P. A phase II clinical study of Suramin in combination with Mitomycin C. VII Mediterranean Congress of Chemotherapy, 2025 May 1990, Barcelona, Spain. Supplement to J Chemotherapy
3(4): 518519, 1991.

Rapoport B L, Swart A, Falkson G, Stevens K. Alpha 2b Interferon in the treatment of “ITPlike syndrome” in cancer patients. 31st Annual Congress of the Federation of South African Societies of Pathology, Warmbaths, p 116 (# H9),
30 June3 July 1991.

Rapoport B L, Rassalski T K, Uys A, Falkson G. Phase II study of Myleran induction followed by `2b Interferon maintenance in patients with chronic myeloid leukaemia. 31st Annual Congress of the Federation of South African Societies of Pathology, Warmbaths, p 122 (# H15), 30 June3 July 1991.

Rapoport B L, Falkson C I, Uys A, KerenRosenberg S, Falkson G, Stevens K. Recombinant human erythropoietin in the treatment of cancer related anaemia. 31st Annual Congress of the Federation of South African Societies of Pathology, Warmbaths, p 124 (# H17), 30 June3 July 1991.

Rapoport B L, Ansell S M, van Eeden E B, Falkson G. Alpha 2b Interferon in chronic myeloproliferative disorders. 31st Annual Congress of the Federation of South African Societies of Pathology, Warmbaths, p 128 (# H21), 30 June3 July 1991.

Rapoport B L, Uys A, CocciaPortugal M A, Raats J I, Falkson G. Experience with GMCSF in the Department of Medical Oncology, University of Pretoria. 31st Annual Congress of the Federation of South African Societies of Pathology, Warmbaths, p 130 (# H23), 30 June3 July 1991.

Rapoport B L, Ansell SM, de Wet M. Fase II kliniese proef van Suramin in kombinasie met MitomisienC in pasi nte met hormoon weerstandbiedende prostaatkanker. Fakulteitsdag, Universiteit van Pretoria, p P13, 1991.

Ansell S M, Rapoport B L, Raats J I, Moeken R, Falkson G. The importance of the rate of tumour response in patients with advanced ovarian cancer. 4th S A Congress of Gynaecological Oncology, Pretoria, p 46, 1991

1990 Rapoport B L, Falkson G, de Wet M. A Phase II Clinical trial of Iphosphamide and Mesna alternating with Etoposide and Cisplatinum in the treatment of small cell carcinoma of the lung. Second International Conference on Small Cell Lung
Cancer, Milano Maritimma (Revenna), Italy, p 154, May 1112, 1990.

Rapoport B L, Falkson G, Ansell S, de Wet M. Phase II Clinical study of Suramin in combination with MitomycinC. 7th Mediterranean Congress of Chemotherapy, Barcelona, Spain, p 131 (#543), May 2025, 1990.

Rapoport B L. Testicular Cancer. A curable disease with long term complications. 18th Biennial Urology Congress, p 84, April 1990.

Rapoport B L, Falkson G, de Wet M, Ansell S M. Phase II Clinical study of Suramin in combination with MitomycinC. 3rd National Scientific Congress South African Society of Medical Oncology, October 1990.

Rapoport B L, Falkson G, de Wet M. A Phase II Clinical trial of Iphosphamide and Mesna alternating with Etoposide and CisPlatinum in the treatment of small cell carcinoma of the lung. 3rd National Scientific Congress South African
Society of Medical Oncology, October 1990.

Rapoport B L, Falkson G. Testicular Cancer. A curable disease with long term complications. 3rd National Scientific Congress South African Society of Medical Oncology, October 1990.

Rapoport B L, Falkson H C, Steyn M E, Meyer B J. Plasma Melatonien in pasiente met borskanker. S Afr Med J 76: 695, 1989.

Rapoport B L, Chasen M R, Ruff P, van Zyl L, Falkson G. Iphosphamide alternating with Etoposide and CisPlatinum in the Treatment of Small Cell Lung Cancer. 2nd Scientific Congress – South African Society of Medical Oncology, Pretoria, October 1988.

Rapoport B L, Ruff P, Falkson G. Prognostic Factors in the Survival of patients with Multiple Myeloma. 3rd Congress – South African Lymphoma Study Group, Pretoria 1988.

PUBLICATIONS

PUBLICATIONS ARCHIVE

Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartsberg LS, Petrenciuc O, Shan M, Gradishar WJ. A phase 3 Trial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast Cancer (the RESILIENCE study): study protocol for a randomized controlled trial. Trials. 2013 Jul 22;14:228. doi: 10.1186/1745-6215-14-228.

Klastersky J, Raftopoulos H, Rapoport B, The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. Support Care Cancer. 2013 Jun;21(6):1793-5. doi: 10.1007/s00520-013-1776-9. Epub 2013 Mar 24.

Kwofie L, Rapoport BL, Fickl H, Meyer PW, Rheeder P, Hlope H, Anderson R, Tintinger GR. Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia: a pilot study. Ann Hematol. 2012 Apr;91(4):605-11. doi: 10.1007/s00277-011-1339-4.

Paesmans M, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Ameye L. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer. 2011 Jul;19(7):1001-8. doi: 10.1007/s00520-010-0925-7. Epub 2010 Jul 2.Herrstedt J, Rapoport B, Warr D, Roila F, Bria E, Rittenberg C, Hesketh PJ. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2011 Mar;19 Suppl 1:S15-23. doi: 10.1007/s00520-010-0951-5. Epub 2010 Aug 2.Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791.x.Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity–state of the art. Support Care Cancer. 2011 Mar;19 Suppl 1:S43-7. doi: 10.1007/s00520-010-1003-x. Epub 2010 Oct 24.Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791.x.Booth CM, Rapoport B. Uptake of novel medical therapies in the general population. Curr Oncol. 2011 Jun;18(3):105-8.Rapoport BL. Management of the cancer patient with infection and neutropenia. Semin Oncol. 2011 Jun;38(3):424-30. doi: 10.1053/j.seminoncol.2011.03.013.
Hesketh PJ, Bosnjak SM, Nikolic V, Rapoport B. Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer. 2011 Dec;19(12):2063-6. doi: 10.1007/s00520-011-1286-6.

Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010 Apr;18(4):509-22. doi: 10.1007/s00520-009-0744-x. Epub 2010 Feb 10.Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer. 2011 Mar;19 Suppl 1:S1-4. doi: 10.1007/s00520-010-0920-z. Epub 2010 May 26.Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010 May;21 Suppl 5:v232-43. doi: 10.1093/annonc/mdq194.

Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010 Apr;18(4):423-31. doi: 10.1007/s00520-009-0680-9. Epub 2009 Jul 1.Rapoport BL, Vorobiof DA, Slabber C, Alberts AS, Hlophe HS, Mohammed C. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer. 2009 Aug;19(6):1137-41. doi: 10.1111/IGC.0b013e3181a8b938.

Rapoport BL, Uys A. Malaria parasitemia associated with febrile neutropenia in African patients undergoing chemotherapy for haematological malignancies. A report of three patients. Chemotherapy. 2008;54(2):117-9. doi: 10.1159/000118663. Epub 2008 Feb 26.

Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH; Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. Eastern Cooperative Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):418-23Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007 Nov;30 Suppl 1:S51-9. Epub 2007 Aug 8.Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl). 2007 Nov;16(6):475-83.

Marty M, Espié M, Llombart A, Monnier A, Rapoport BL, Stahalova V. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Dexrazoxane Study Group. Ann Oncol. 2006 Apr;17(4):614-22. Epub 2006 Jan 19.

Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, Aapro M. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer. 2005 Feb;13(2):112-6. Epub 2004 Oct 9.

De Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans J K, Horgan K J. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy. A combined analysis of two randomized, placebo-controlled Phase III clinical trials. Eur J Cancer 40: 403-410, 2004

Uys A, Rapoport B L, Anderson R. Febrile neutropenia : a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index. Support Care in Ca, 12: 555-560, 2004

Vorobiof DA, Rapoport BL, Chasen MR, Slabber CF, McMichael GB, Eek RW, Mohammed C. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: A multicentre Phase II study. Breast, 13: 219-226, 2004

Kuehr T, Ruff P, Rapoport BL, Falk S, Daniel F, Jacobs C, Davidson N, Thaler J, Boussard B, Carmichael J. Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer. 2004 Jul 16;4:36.

Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity–an update. Support Care Cancer. 2005 Feb;13(2):80-4. Epub 2004 Dec 14.

Biganzoll L, Cufer T, Bruning P, Dcoleman R E, Duchateau L, Rapoport B, Nooij M, Delhaye F, Miles D, Sulkes A, Hamilton A, Piccart M. Doxorubicin-Paclitaxel. A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer Multicenter Trial. Cancer, 97: 40-45, 2003

Abratt R P, Eek R, Goedhals L, Rapoport B, Slabber C F, Vorobiof D A. Guidelines for CPD accreditation of the South African Society of Medical Oncology. S A Med J 93: 728, 2003

Vorobiof DA, Rapoport BL, Chasen MR, Cohen GL, Mahomed R, Karime M. Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer : active combination with low incidence of peripheral neuropathy. Int J Gynae Ca 13, 287-291, 2003

Vorobiof DA, Rapoport BL, Mahomed R, Karime M. Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Res 13: 201-203, 2003

Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M; Epoetin Alfa Study Group. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol. 2003 Dec;21(4):169-80.

Abratt RP, Vorobiof DA, Goedhals L, Rapoport B, Ruff P, Slabber CF. Scientific fraud and international research.
J Clin Oncol. 2001 Aug 1;19(15):3592.

Vorobiof DA, Abratt R, Rapoport B, Ruff P, Slabber C, Goedhals L. Scientific misconduct in cancer clinical trials.
S Afr Med J 2001 Aug;91(8):614-5

Littlewood T J, Bajetta E, Nortier J W R, Vercammen E, Rapoport B. Effect of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 19: 2865-2874, 2001

Management of Anemia in Patients Receiving Chemotherapy. Justin S. Waters, Mary E.R. O’Brien, and Sue Ashley. Response from T. J. Littlewood, E. Bajetta, J. W.R. Nortier, E. Vercammen, B. Rapoport, and for the Epoetin Alfa Study Group JCO Jan 15, 2002:601-603

Abratt R P, Vorobiof D A, Goedhals L, Rapoport B, Ruff P, Slabber C F. Scientific fraud and international research. J Clin Oncol 19: 3592, 2001

Giles FJ, Wickham NR, Rapoport BL, Somlo G, Lim SW, Shan J, Lynott AM. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol 2000 Mar;63(3):125-30

Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
J Clin Oncol 2000 Aug;18(16):3038-51

Davidson N, Rapoport B, Erikstein B, L’Esperance B, Ruff P, Paska W, Miller I, Curtis P. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group.
Clin Ther 1999 Mar;21(3):492-502

Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
J Clin Oncol 1999 May;17(5):1413-24

Rapoport BL, Sussmann O, Herrera MV, Schlaeffer F, Otero JC, Pavlovsky S, Iglesias L, Stein G, Charnas R, Heitlinger E, Handschin J. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. Standard In-patient care.
Chemotherapy 1999 Nov-Dec;45(6):466-76

Krzakowski M, Graham E, Goedhals L, Joly F, Pawlicki M, Rapoport B, Yelle L, Lees J, McQuade B. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group.
Anticancer Drugs 1998 Aug;9(7):593-8

Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Aapro MS, Alaki M, Murawsky M, Riva A. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Oncology (Huntingt) 1997 Aug;11 (8 Suppl 8): 25-30

de Wet M, Falkson G, Rapoport B L. Small Cell Lung Cancer: Analysis of factor influencing the response to treatment and survival.
Oncology 51: 523-534, 1994.

Rapoport B L, Ruff P. Lymphoma in Africa. S A Lymphoma Study Group Biennial Congress. (Congress Report)
S Afr Med J 83: 7273, 1993.

De Wet M, Falkson G, Rapoport B L. Repeated use of Granisetron in patients receiving cytostatic agents.
Cancer 71:40434049, 1993.

Rapoport B L, Falkson G, Raats J I, de Wet M, Lotz B P, Potgieter H C. Suramin in combination with mitomycin C in hormoneresistant prostate cancer. A Phase II clinical study.
Annals Oncol 4: 567573, 1993.

KerenRosenberg S, Raats J I, Rapoport B L, Falkson G. Somatostatin in the treatment of paraneoplastic diarrhoea in patients with small cell lung cancer. (Letter)
Annals of Oncology 3: p 409, 1992.

Falkson G, Rapoport B L. Lethal toxic epidermal necrolysis during suramin treatment. (Letter)
Eur J Cancer 28A(6/7): 1294, 1992.

Rapoport B L, Falkson G. Phase II clinical study of pirarubicin in hormone resistant prostate cancer.
Investigational New Drugs 10: 119121, 1992

Ansell S M, Rapoport B L, CocciaPortugal M A, Stevens K, Bester C J, Falkson G. Trisomy 5 in Ph+ Chronic Myeloid Leukemia in association with Megakaryocytosis.
Cancer Genet Cytogenet 51: 273275, 1991.

Ansell S M, Jansen van Rensburg E, Rapoport B L, Gresse P, Cloete E V, van Staden A M, Stevens K, Falkson C I, Falkson G. Sister Chromatid exchanges in lymphocyte cultures of patients previously treated with Dibromodulcitol.
Oncology 48: 253257, 1991.

Rapoport B L, Falkson G, Ansell S M, Lotz BP, de Wet M. A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer. Lung Cancer 7: 323328, 1991.

Rapoport B L, Falkson H C, Falkson G. Prognostic factors affecting the survival of patients with multiple myeloma. S Afr Med J 79: 6567, 1991.

Rapoport B L, Falkson G, Ansell S M, de Wet M, Lotz B P. A phase II clinical study of Suramin in combination with Mitomycin C. (Extended Abstract)
Journal of Chemotherapy Suppl 4, pp 518519, 1991.

Rapoport B L, Falkson G, Alberts A S, Eloff P. “Idiopathic thrombocytopenic purpuralike syndrome” treated with Interferon in a patient with lung cancer.
Am J Hematol 34: 7172, 1990.

Falkson G, Falkson H C, Steyn M E, Rapoport B L, Meyer B J. Plasma Melatonien in patients with breast cancer.
Oncology 47: 401405, 1990.

Alberts A S, Falkson G, Rapoport B L, Uys A. A Phase II study of Idarubicin and Prednisone in multiple myeloma.
Tumori 76: 465466, 1990.

Raats J I, Rapoport B L, Falkson G. Granulosiet en makrofaagkolonie stimulerende faktore: beginsels en kliniese toepassing.
Geneeskunde 32 (10): 26, 1990.

A study of autoantibodies in chronic mycobacterial infections in black South Africans. Dissertation submitted in partial fulfillment of the Master of Medicine Degree in the Branch of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa.

INVITED LECTURES

Presented Posters and Oral Presentations at Various Local South African and International Scientific Meetings (including ASCO, MASCC and ESMO).

2013 INVITED LECTURES

BL Rapoport. Febrile Neutropenia. What is new since MASCC 2012. MASCC/ISOO 2012 International Symposium June 2013, Berlin, Germany.

ARCHIVE

BL Rapoport. Febrile Neutropenia: Controversies and Process, MASCC/ISOO 2011 International Symposium June 2012, New York USA.
BL Rapoport. Febrile Neutropenia. What is new since MASCC 2012. MASCC/ISOO 2012 International Symposium June 2013, Berlin, Germany.

BL Rapoport. Opportunistic Infections. MASCC/ISOO 2011 International Symposium June 2011, Athens, Greece

BL Rapoport. Opportunistic Infections. MASCC/ISOO 2011 International Symposium June 2010, Rome, Italy